| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-07-06 | Innate Pharma (France) Paoli-Calmettes Institute (France) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2015-07-02 | BiogenIdec (USA - MA) AGTC (USA - FL) | gene therapies | ophtalmological diseases including X-linked Retinoschisis and X-Linked Retinitis Pigmentosa | collaboration development |
Ophtalmological diseases - Genetic diseases - Rare diseases | Collaboration agreement |
| 2015-07-02 | Oncobiologics (USA - NJ) | nomination |
Nomination | |||
| 2015-07-02 | Genticel (France) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2015-07-02 | Elsalys Biotech (France) Mablife (France) | anti-CD160 antibody | product acquisition |
Cancer - Oncology - Ophtalmological diseases | Product acquisition | |
| 2015-07-02 | Acucela (USA - MA) | nomination |
Ophtalmological diseases | Nomination | ||
| 2015-07-02 | Alexion Pharmaceuticals (USA - CT) Lonza (Switzerland) | production manufacturing |
Rare diseases - Genetic diseases | Production agreement | ||
| 2015-07-02 | Provectus Pharmaceuticals (USA - TN) Boehringer Ingelheim (Germany) | PV-10 | commercialisation |
Cancer - Oncology | Commercialisation agreement | |
| 2015-07-01 | Baxter (USA - IL) Baxalta (USA - IL) | establishment of a new company in the US |
Rare diseases - Genetic diseases - Hematological diseases - Cancer - Oncology - Inflammatory diseases - Autoimmune diseases | Establishment of a new subsidiary in the US | ||
| 2015-07-01 | Hybrigenics (France) | nomination |
Nomination | |||
| 2015-07-01 | CEVEC Pharmaceuticals (Germany) Biotest (Germany) | CAP®Go technology | hemophilia | licensing |
Technology - Services - Genetic diseases - Hematological diseases - Rare diseases | Licensing agreement |
| 2015-07-01 | Sarepta Therapeutics (USA - MA) | nomination |
Rare diseases - Genetic diseases - Neuromuscular diseases | Nomination | ||
| 2015-06-30 | Advanced Accelerator Applications (France) FUJIFILM RI Pharma (Japan) | Lutathera® (radiolabeled somatostatin analog) | inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors | distribution |
Cancer - Oncology | Distribution agreement |
| 2015-06-30 | CMC Biologics (Denmark - USA) | expansion of a production plant |
Technology - Services | Construction of a production plant | ||
| 2015-06-30 | Faron Pharmaceuticals (Finland) the Turku PET Center (Finland) | Clevegen® | collaboration R&D |
Cancer - Oncology | Collaboration agreement | |
| 2015-06-29 | Abbvie (USA - IL) | construction of new premises |
Autoimmune diseases - Medical devices | Construction of new premises | ||
| 2015-06-29 | Eli Lilly (USA - IN) Immunocore (UK) | IMCgp100, in combination with galunisertib (LY2157299) and merestinib (LY2801653) | metastatic cutaneous melanoma, uveal melanoma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-06-29 | Proteros biostructures (Germany) | nomination |
Nomination | |||
| 2015-06-29 | Immune Pharmaceuticals (USA - MA, Israel) Yissum (Israel) | topical nanoparticle formulation of Amiket | neuropathic pain | licensing |
CNS diseases | Licensing agreement |
| 2015-06-29 | Cyclacel (UK) Manros Therapeutics (France) | seliciclib | cystic fibrosis | collaboration development licensing |
Rare diseases - Genetic diseases | Collaboration agreement |
